Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr 15;117(8):1640-8.
doi: 10.1002/cncr.25731. Epub 2010 Nov 8.

Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use

N Jewel Samadder  1 , Bhramar Mukherjee, Shu-Chen Huang, Jaeil Ahn, Hedy S Rennert, Joel K Greenson, Gad Rennert, Stephen B Gruber
Affiliations

Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use

N Jewel Samadder et al. Cancer. .

Abstract

Background: Statins and nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with reduced risk of colorectal cancer (CRC) in some studies. The objective of this study was to quantify the relative risk of inflammatory bowel disease (IBD) as a risk factor for CRC and to estimate whether this risk may be modified by long-term use of NSAIDs or statins.

Methods: The Molecular Epidemiology of Colorectal Cancer study is a population-based, case-control study of incident colorectal cancer in northern Israel and controls matched by age, sex, clinic, and ethnicity. Personal histories of IBD and medication use were measured by structured, in-person interview. The relative risk of IBD and effect modification by statins and NSAIDs were quantified by conditional and unconditional logistic regression.

Results: Among 1921 matched pairs of CRC cases and controls, a self-reported history of IBD was associated with a 1.9-fold increased risk of CRC (95% confidence interval [CI], 1.12-3.26). Long-term statin use was associated with a reduced risk of both IBD-associated CRC (odds ratio [OR] = 0.07; 95% CI, 0.01-0.78) and non-IBD CRC (OR = 0.49; 95% CI, 0.39-0.62). Stratified analysis suggested that statins may be more protective among those with IBD (ratio of OR = 0.14; 95% CI, 0.01-1.31; P = .51), although not statistically significant. NSAID use in patients with a history of IBD was suggestive of reduced risk of CRC but did not reach statistical significance (OR = 0.47; 95% CI, 0.12-1.86).

Conclusions: The risk of CRC was elevated 1.9-fold in patients with IBD. Long-term statin use was associated with reduced risk of CRC in patients with IBD.

PubMed Disclaimer

References

    1. Crohn B, Rosenber H. The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). American Journal of Medical Science. 1925;170:220–8.
    1. Weedon DD, Shorter RG, Ilstrup DM, Huizenga KA, Taylor WF. Crohn's disease and cancer. N Engl J Med. 1973;289(21):1099–103. - PubMed
    1. Gyde SN, Prior P, Macartney JC, Thompson H, Waterhouse JA, Allan RN. Malignancy in Crohn's disease. Gut. 1980;21(12):1024–9. - PMC - PubMed
    1. Gillen CD, Andrews HA, Prior P, Allan RN. Crohn's disease and colorectal cancer. Gut. 1994;35(5):651–5. - PMC - PubMed
    1. Greenstein AJ, Sachar DB, Smith H, Janowitz HD, Aufses AH., Jr A comparison of cancer risk in Crohn's disease and ulcerative colitis. Cancer. 1981;48(12):2742–5. - PubMed

Substances